BioCentury
ARTICLE | Company News

DRAX submits NDS for Ziconotide

December 14, 2000 8:00 AM UTC

Draxis Health (DRAX; TSE:DAX) submitted an NDS in Canada for Ziconotide, an N-type neuronal calcium channel blocker to treat chronic intractable pain. DRAX licensed Canadian rights to Zicotonide from ...